Q-omics provides the consensus-scored SMPD4BP profile across patient tissues and cancer cell-line models. SMPD4BP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMPD4BP is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SMPD4BP RNA expression shows 19,607 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where SMPD4BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMPD4BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMPD4BP survival associations across molecular data types. SMPD4BP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMPD4BP RNA expression–survival associations across cancer types. High SMPD4BP expression shows unfavorable associations in ACC, KIRC, COAD and LIHC, but favorable associations in HNSC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMPD4BP RNA expression.
This table summarizes SMPD4BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMPD4BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMPD4BP shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, LIHC, HNSC and BLCA. The COAD box plot shows higher SMPD4BP RNA expression in tumor versus normal tissue (log2 FC = +1.195, t-test p < 0.001).
This table shows molecular features associated with SMPD4BP in patient tissues and cancer cell lines. In patient samples, SMPD4BP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
